Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like Doing it Right: The Man Who Blew Up Theranos Started His Own Medical Testing Biotech October 3, 2017 <b>ConfirmMDx</b> Study Provides Further Validation Of Epigenetic Risk Profile August 9, 2017 Why This SoCal Pharma Could Be Your Best Bet on Alzheimer's April 24, 2017